Skip to main content

Advertisement

Table 2 Absolute and percentage change in eGFR in patients with CKD stages 3 and 4

From: Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

Parameter PGL q2wks (n = 42) PGL q4wks (n = 41) Placebo (n = 20) P value*
Absolute change in eGFR
    Mean (SD) −2.8 (8.2) −1.1 (11.2) −2.7 (8.1) 0.607
    Median (min, max) −4.12 (−19.6, 19.7) −2.63 (−15.2, 54.6) −2.54 (−18.6, 16.1)  
Percent change in eGFR
    Mean (SD) −4.2 (24.5) −4.4 (27.3) −5.8 (21.2) 0.853
    Median (min, max) −10.4 (−45.5, 94.2) −9.6 (−57.7, 106.6) −6.1 (−46.0, 52.3)  
  1. eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; PGL, pegloticase; q2wks, every 2 weeks; q4wks, every 4 weeks; SD, standard deviation.
  2. *A general linear model F-test, adjusted for age, sex, and race/ethnicity, was used to assess the overall impact of treatment.